160 related articles for article (PubMed ID: 29035388)
1. A novel HER2 gene body enhancer contributes to HER2 expression.
Liu Q; Kulak MV; Borcherding N; Maina PK; Zhang W; Weigel RJ; Qi HH
Oncogene; 2018 Feb; 37(5):687-694. PubMed ID: 29035388
[TBL] [Abstract][Full Text] [Related]
2. Analysis of H3K4me3 and H3K27me3 bivalent promotors in HER2+ breast cancer cell lines reveals variations depending on estrogen receptor status and significantly correlates with gene expression.
Kaukonen D; Kaukonen R; Polit L; Hennessy BT; Lund R; Madden SF
BMC Med Genomics; 2020 Jul; 13(1):92. PubMed ID: 32620123
[TBL] [Abstract][Full Text] [Related]
3. Towards sustained silencing of HER2/neu in cancer by epigenetic editing.
Falahi F; Huisman C; Kazemier HG; van der Vlies P; Kok K; Hospers GA; Rots MG
Mol Cancer Res; 2013 Sep; 11(9):1029-39. PubMed ID: 23814024
[TBL] [Abstract][Full Text] [Related]
4. A
Wu VT; Kiriazov B; Koch KE; Gu VW; Beck AC; Borcherding N; Li T; Addo P; Wehrspan ZJ; Zhang W; Braun TA; Brown BJ; Band V; Band H; Kulak MV; Weigel RJ
Mol Cancer Res; 2020 Jan; 18(1):46-56. PubMed ID: 31619506
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies.
Singla H; Ludhiadch A; Kaur RP; Chander H; Kumar V; Munshi A
Eur J Med Chem; 2017 Dec; 142():316-327. PubMed ID: 28800870
[TBL] [Abstract][Full Text] [Related]
6. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.
Newman SP; Bates NP; Vernimmen D; Parker MG; Hurst HC
Oncogene; 2000 Jan; 19(4):490-7. PubMed ID: 10698518
[TBL] [Abstract][Full Text] [Related]
7. Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits.
Rhie SK; Guo Y; Tak YG; Yao L; Shen H; Coetzee GA; Laird PW; Farnham PJ
Epigenetics Chromatin; 2016; 9():50. PubMed ID: 27833659
[TBL] [Abstract][Full Text] [Related]
8. The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.
Lo PK; Lee JS; Liang X; Sukumar S
Cell Signal; 2016 Oct; 28(10):1502-19. PubMed ID: 27377963
[TBL] [Abstract][Full Text] [Related]
9. Human epidermal growth factor receptor 2 inhibits activating transcription factor 7 to promote breast cancer cell migration by activating histone lysine demethylase 1.
Lin J; Mao H; Ji Z; Lin W; Wang T
J Cancer Res Ther; 2021 Nov; 17(5):1192-1201. PubMed ID: 34850767
[TBL] [Abstract][Full Text] [Related]
10. The 5' regulatory sequences of active miR-146a promoters are hypomethylated and associated with euchromatic histone modification marks in B lymphoid cells.
Szenthe K; Koroknai A; Banati F; Bathori Z; Lozsa R; Burgyan J; Wolf H; Salamon D; Nagy K; Niller HH; Minarovits J
Biochem Biophys Res Commun; 2013 Apr; 433(4):489-95. PubMed ID: 23528241
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive epigenetic analyses reveal master regulators driving lung metastasis of breast cancer.
Li K; Xu C; Du Y; Junaid M; Kaushik AC; Wei DQ
J Cell Mol Med; 2019 Aug; 23(8):5415-5431. PubMed ID: 31215771
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
14. Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer.
Dreijerink KMA; Groner AC; Vos ESM; Font-Tello A; Gu L; Chi D; Reyes J; Cook J; Lim E; Lin CY; de Laat W; Rao PK; Long HW; Brown M
Cell Rep; 2017 Mar; 18(10):2359-2372. PubMed ID: 28273452
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
16. Intron 1-Mediated Regulation of
Jameson NM; Ma J; Benitez J; Izurieta A; Han JY; Mendez R; Parisian A; Furnari F
Mol Cancer Res; 2019 Nov; 17(11):2208-2220. PubMed ID: 31444232
[TBL] [Abstract][Full Text] [Related]
17. HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPß isoforms.
Arnal-Estapé A; Tarragona M; Morales M; Guiu M; Nadal C; Massagué J; Gomis RR
Cancer Res; 2010 Dec; 70(23):9927-36. PubMed ID: 21098707
[TBL] [Abstract][Full Text] [Related]
18. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells.
Delacroix L; Begon D; Chatel G; Jackers P; Winkler R
DNA Cell Biol; 2005 Sep; 24(9):582-94. PubMed ID: 16153159
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic mechanisms regulate the prostaglandin E receptor 2 in breast cancer.
To SQ; Takagi K; Miki Y; Suzuki K; Abe E; Yang Y; Sasano H; Simpson ER; Knower KC; Clyne CD
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):331-8. PubMed ID: 22929011
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of OCT4 induced by modulation of histone marks plays crucial role in breast cancer progression.
Kar S; Patra SK
Gene; 2018 Feb; 643():35-45. PubMed ID: 29203199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
